Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Research

Supporting academic research within and outside of the university, we provide specialist analytical chemistry support in the majority through HPLC-MS or HPLC-MS-MS techniques with additional UV-visible absorbance and fluorescence detection abilities.
Bioanalysis

Supporting academic research within and outside ...

The Early Phase Clinical Trials Unit (EPCTU) aims to support the translation of research findings in to clinical practice.
Early Phase Clinical Trials Unit

The Early Phase Clinical Trials Unit (EPCTU) aims ...

Flow Cytometry is a technology enabling the measurement of numerous parameters, via fluoroescence signalling, in your suspension sample of cells/particles.
Flow Cytometry

Flow Cytometry is a technology enabling the ...

The Live Tissue Facility is designed to boost the translational impact of oncological research without users having to independently create ethics applications and collection logistics.
Live Tissue Facility

The Live Tissue Facility is designed to boost the ...

The Mechanical Workshop delivers an on-site fabrication facility for custom-made, precision mechanical items for use in scientific research.
Mechanical Workshop

The Mechanical Workshop delivers an on-site ...

The Microscopy SRF aims to provide research groups with imaging technologies to investigate cellular processes both in vitro and in vivo.
Microscopy

The Microscopy SRF aims to provide research ...

The Oncology Clinical Trials Office (OCTO) provides clinical trial management support to investigators across the CRUK Oxford Centre to manage trials from concept to completion.
Oncology Clinical Trials Office (OCTO)

The Oncology Clinical Trials Office (OCTO) ...

The PET Radiochemistry and Radiopharmacy core supports radiochemistry-dependent research programmes and provide GMP-grade PET radiopharmaceuticals for clinical trials.
PET Radiochemistry and Radiopharmacy (PROx)

The PET Radiochemistry and Radiopharmacy core ...

State-of-the art platforms for in vivo study of disease models
Pre-Clinical Imaging

State-of-the art platforms for in vivo study of ...

Proteomics studies proteins on a large scale. Proteins are vital to living organisms and their multi-functional characteristics act as potential targets for drug therapies. Therefore, proteomics can be used for biomarker and target discovery, drug profiling and target validation.
Proteomics

Proteomics studies proteins on a large scale. ...

The Radiation Biophysics Facility develops and supports a unique range of radiation resources and techniques along with providing associated expertise.
Radiation Biophysics

The Radiation Biophysics Facility develops and ...

We provide tools, skills and training on analysis of biomedical data. Our expertise covers areas ranging from applied statistics to computational and functional genomics.
The Bioinformatics Hub

We provide tools, skills and training on analysis ...

Translational Histopathology
Translational Histopathology

Key Research Links

Latest Research News

New Fellow of the Society for Radiation Protection

Many congratulations to Dr Mark Hill, who has become a Fellow of the Society for Radiation Protection (FSRP).

Integrating Cancer Imaging Biomarker Clinical Research Across the UK

UK National Cancer Imaging Translational Accelerator (NCITA) establishes infrastructure for validation and adoption of cancer imaging biomarkers as decision-making tools in clinical trials and NHS practice. Researchers and medical experts from nine world-leading medical imaging centres across the UK come together to form an integrated infrastructure for standardising and validating cancer imaging biomarkers for clinical use.

Ramandan Group publish original scientific article in Nature Communications

Group of Professor Kristijan Ramadan has published an original scientific article in Nature Communications today. The article has the first report of a new autophagy receptor TEX264, which may be involved in tumours developing drug resistance.

More news